Type 2 Diabetes, Obesity and Cortisol Excess

Launched by ISTITUTO AUXOLOGICO ITALIANO · Feb 26, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the relationship between obesity, type 2 diabetes, and a condition called hidden hypercortisolism (HidHyCo), which means having high levels of a hormone called cortisol that may not be obvious. Researchers want to find out how common this condition is among people with type 2 diabetes and obesity, as well as identify the symptoms and characteristics that might be linked to it. The trial is currently looking for participants, including adults between the ages of 65 and 75 who have both type 2 diabetes and obesity.

To participate, individuals should not be pregnant, breastfeeding, or have certain health conditions like sleep apnea or specific hormonal issues. Those without type 2 diabetes but who are obese may also be included in the study. Participants can expect to undergo assessments to help researchers understand how HidHyCo affects their health. This study aims to improve our understanding of how cortisol and these conditions interact, which could lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients with T2D and Obesity
• Exclusion Criteria:
• • pregnancy/breast feeding,
• • sleep apnea,
• • prepuberal onset of hypertension, hormonal hypersecreting adrenal mass,
• • symptoms of hypercortisolism;
• • already known secondary hypertension;
• • conditions associated with increased hypothalamic-pituitary-adrenal (HPA) axis activity, -severe autoimmune/rheumatologic and hematologic diseases, alcoholism, kidney disease (glomerular filtration rate \<60)
• • drugs influencing the HPA axis activity. For inclusion in Group 2 the presence of T2D will be an exclusion criteria